Cyclosomatostatin- and haloperidol-induced catalepsy in Wistar rats: Differential responsiveness to sleep deprivation

Ionov, Ilya D.; Pushinskaya, Irina I.; Gorev, Nicholas P; Frenkel, David D.

doi:10.1016/j.neulet.2018.07.012

Cited by 3 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The haloperidol‐induced catalepsy is usually used as the main test of the study. Some studies, however, have used haloperidol for comparison purposes to explore if other drugs are also efficient in producing catalepsy (Haraguchi et al., 1996; Ionov & Pushinskaya, 2013; Ionov et al., 2018; Ionov & Severtsev, 2012b; Neves et al., 2003). This finding shows the importance and reliability of the haloperidol‐induced catalepsy animal model.…”

Section: Discussionmentioning

confidence: 99%

“…Regarding the doses of haloperidol, a great variety was found, both for rats and mice (Figure 3). Although responses to haloperidol vary widely among studies, the cataleptic effects of haloperidol emerge especially at doses of 0.5 mg/kg and higher (Ionov et al., 2018; Ionov & Severtsev, 2012a; Koranda et al., 2016; Luthra et al., 2008; Mandhane et al., 1997; Marazziti et al., 2007). The most used dose was 1.0 mg/kg, capable of inducing catalepsy regardless of the species or strain used (Darbaky et al., 2003; Kasture, Suvarna, et al., 2009; Łażewska et al., 2020; Melo‐Thomas & Thomas, 2015).…”

Section: Discussionmentioning

confidence: 99%

“…Check the model for pathophysiological/ behavioral characteristics already established for parkinsonism 35 1981 and 2020 (Clark et al, 2009;Antkiewicz-Michaluk et al, 2000;Alvarez-Cervera et al, 2005;Colombo et al, 2013;Ionov & Pushinskaya, 2013;Makhija & Jagtap, 2014;Zolbanin et al, 2014;Melo-Thomas & Thomas, 2015;Tonelli et al, 2017;Ahmadi et al, 2018;Ionov et al, 2018;Barroca et al, 2019;Schallert & Teitelbaum, 1981;Fowler & Mortell, 1992;Hyde et al, 1995;Frank & Schmidt, 2003;Srinivasan & Schmidt, 2003a;Marchese et al, 2004;Riedinger et al, 2011;Chopde et al, 1995;Weihmuller et al, 1988a;Luthra et al, 2008;Mabrouk et al, 2010;Cannella et al, 2015;Hagino et al, 2015;Ionov & Severtsev, 2012b;Haraguchi et al, 1996;Haraguchi et al, 1997;Nasu et al, 2000;Pires et al, 2003;Ardayfio et al, 2010) Explore potential new pathophysiological/ behavioral characteristics for parkinsonism 49 1981 and 2019 (Greco et al, 2010;Scheel-Krüger & Magelund, 1981;Miwa et al, 1996;Maj et al, 1999;Vetulani et al, 2003;Konieczny et al, 2007;<...>…”

Section: First and Last Year Of Publication Referencesmentioning

confidence: 99%

See 2 more Smart Citations

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Waku

Magalhães

Alves

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

Several useful animal models for parkinsonism have been developed so far. Haloperidol‐induced catalepsy is often used as a rodent model for the study of motor impairments observed in Parkinson's disease and related disorders and for the screening of potential antiparkinsonian compounds. The objective of this systematic review is to identify publications that used the haloperidol‐induced catalepsy model for parkinsonism and to explore the methodological characteristics and the main questions addressed in these studies. A careful systematic search of the literature was carried out by accessing articles in three different databases: Web of Science, PubMed and SCOPUS. The selection and inclusion of studies were performed based on the abstract and, subsequently, on full‐text analysis. Data extraction included the objective of the study, study design and outcome of interest. Two hundred and fifty‐five articles were included in the review. Publication years ranged from 1981 to 2020. Most studies used the model to explore the effects of potential treatments for parkinsonism. Although the methodological characteristics used are quite varied, most studies used Wistar rats as experimental subjects. The most frequent dose of haloperidol used was 1.0 mg/kg, and the horizontal bar test was the most used to assess catalepsy. The data presented here provide a framework for an evidence‐based approach to the design of preclinical research on parkinsonism using the haloperidol‐induced catalepsy model. This model has been used routinely and successfully and is likely to continue to play a critical role in the ongoing search for the next generation of therapeutic interventions for parkinsonism.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: First and Last Year Of Publication Referencesmentioning

confidence: 99%

See 1 more Smart Citation

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Waku

Magalhães

Alves

et al. 2021

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…The severity of the catalepsy was estimated by awarding the points. The response of each animal was measured for 4 h at every 1-h interval on the seventh day of the experiment after administering standard and synthesised compounds [12].…”

Section: Behavioural Testmentioning

confidence: 99%

Effect of novel phenothiazine derivatives on brain dopamine in Wistar rats

Gopi¹,

Sastry

Dhanaraju³

2019

Beni-Suef Univ J Basic Appl Sci

View full text Add to dashboard Cite

Background: Neurotransmitters are involved in several functions in the brain and the body of living things. Changes in the level of neurotransmitters in the brain are associated with several illnesses. Some of the drugs are controlling the neurotransmitter by adjusting the level in the brain and are exclusively used in the treatment of psychological disorders. The purpose of the study was to find out the effect of novel synthesised phenothiazine derivatives (GC1, GC2 and GC8) either alone (7.5 mg/kg or 15 mg/kg, oral) or in combination with amphetamine on the experimental animals. Results: Dopamine level in rat brain was estimated by a spectroscopic method using the UV-visible double beam spectrophotometer at 735 nm. The results revealed that these derivatives blocked the brain dopamine level significantly. The compound GC8 (15 mg/kg) significantly reduced the level of dopamine (0.151 ± 0.04, 0.284 ± 0.03) as similar to that of a standard drug. Furthermore, compounds GC2 (15 mg/kg) and GC1 (15 mg/kg) exhibited a varying level of dopamine inhibition level and have been found at 0.203 ± 0.06 μg/ml, 0.302 ± 0.04 μg/ml, 0.234 ± 0.02 μg/ml and 0.318 ± 0.07 μg/ml, respectively, after the administration of these derivatives either alone or in combination with amphetamine. Conclusions: The study revealed that the compound 2-amino-6-(3-hydroxy-4-methyl phenyl) pyrimidine-4-yl) (7-chloro-10-(3-(N, N-dimethylamino) propyl)-10H-phenothiazine-3-yl) methanone (GC8, 15 mg/kg) extensively reduced the dopamine level. The order of dopamine-inhibiting effect of the selected compound was found to be GC8 > GC2 > GC1. The increased body weight and relative brain-body weight were also observed in the tested animals due to more intake of food and fluid retention.

show abstract

Synthesis and antiparkinsonian activity of nanocomposite of chitosan-tripolyphosphate-Mucuna pruriens L extract (CS-TPP-MP)

Sardjono

Fauziyah

Puspitasari

et al. 2020

IOP Conf. Ser.: Mater. Sci. Eng.

View full text Add to dashboard Cite

Mucuna pruriens L. (MP) has antiparkinsonian activity because it contains levodopa that acts as a dopamine precursor and plays a role to stimulate dopaminergic receptors in Parkinson's sufferers. The therapeutic efficacy of MP extract can be improved by using a nano drug carrier system, such as chitosan-tripolyphosphate (CS-TPP). This study aims to synthesize, characterize, and evaluate antiparkinsonian activity of chitosan-tripolyphosphate-MP extract (CS-TPP-MP) nanocomposite in mice. MP seed powder was extracted by maceration method using water-ethanol (1:1) by adding citric acid until it reached pH 3. The CS-TPP-MP nanocomposite was synthesized by using ionic gelation method with variations in reactant composition and reaction time. The CS-TPP-MP nanocomposite was characterized by Scanning Electron Microscopy-Energy Dispersive X-ray (SEM-EDX), X-Ray Diffraction (XRD) and Fourier-Transform Infrared (FTIR) Spectroscopy. Catalepsy test was performed to find the antiparkinsonian activity level of CS-TPP-MP nanocomposite at doses of 5, 10, 15, 20, and 25 mg/kg body weight. Based on the results of CS-TPP-MP synthesis, it was found that the reactant composition (CS-TPP:MP) of 1:3 with reaction time of 20 minutes produced the highest yield (14.21%.) SEM-EDX characterization showed that the morphology of CS-TPP-MP nanocomposite was predominantly spherical and the size was approximately 120-170 nm with a composition of C = 55.43%, O = 30.46%, N = 13.46%, P = 0.44%. XRD diffractogram showed that CS-TPP-MP nanocomposite has amorphous structure. FTIR analysis showed the appearance of absorption at wavelength of 1643.35 cm−1 which proved the interaction between the primary amine group of chitosan and the carbonyl group of EMP. Catalepsy test demonstrated that CS-TPP-MP nanocomposite at the doses of 5, 10, 15, 20, and 25 mg/kg body weight could reduce catalepsy symptoms in mice significantly, and the best dosage was 20 mg/kg body weight.

show abstract

Cyclosomatostatin- and haloperidol-induced catalepsy in Wistar rats: Differential responsiveness to sleep deprivation

Cited by 3 publications

References 47 publications

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Effect of novel phenothiazine derivatives on brain dopamine in Wistar rats

Synthesis and antiparkinsonian activity of nanocomposite of chitosan-tripolyphosphate-Mucuna pruriens L extract (CS-TPP-MP)

Contact Info

Product

Resources

About